No Data
No Data
Guobang Pharmaceutical: Guobang Pharmaceutical Report for the First Quarter of 2025
Guobang Pharmaceutical\'s 2025 First Quarter Report
Express News | Guobang Pharmaceutical: In the first quarter of 2025, the net income is 0.215 billion yuan, an increase of 8.17% year-on-year.
Guobang Pharmaceutical (605507): Q1 performance slightly exceeds market expectations, achieving steady growth under a high base.
On April 15, 2025, the company released its Q1 2025 report, achieving revenue of 1.44 billion yuan (YoY +7.57%) and a net income attributable to the parent company of 0.215 billion yuan (
Guobang Pharmaceutical (605507.SH): The impact of the increased tariffs on the company is very limited.
On April 8, Gelonghui reported that Guobang Pharmaceutical (605507.SH) stated on the investor interaction platform that the impact of the increased tariffs on the company is very limited. The company's products, including florfenicol and tylosin, have passed the FDA certification in the USA, and are currently in the phase of continuous expansion. At present, the export business to the USA accounts for a low proportion, with projected revenue from the USA market for the 2024 fiscal year amounting to 44.9191 million yuan, and a net income of 3.3689 million yuan, making up 0.43% of the company's net income attributable to the parent.
Express News | Guobang Pharmaceutical: has repurchased 0.5168 million shares, using a total amount of 9.9986 million yuan.